Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch
17 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/theravance-biopharma-to-conduct-investor-meetings-during-the-jp-morgan-43rd-annual-healthcare-conference-302333431.html
20 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302311022.html
12 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-third-quarter-2024-financial-results-and-announces-initiatives-to-unlock-shareholder-value-302303317.html
24 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-third-quarter-2024-financial-results-on-november-12-2024-302285433.html
18 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/theravance-announces-publication-of-yupelri-revefenacin-area-under-the-curve-spirometry-analysis-in-the-international-journal-of-chronic-obstructive-pulmonary-disease-302280400.html
27 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302231359.html
Details:
Yupelri (revefenacin) is a novel small molecule, M3 receptor inhibitor. It is under phase 4 clinical studies in patients with severe to very severe chronic obstructive pulmonary disease (COPD).
Lead Product(s): Revefenacin
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Yupelri
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theravance Biopharma Announces Results from Phase 4 YUPELRI® PIFR-2 Study in COPD Patients
Details : Yupelri (revefenacin) is a novel small molecule, M3 receptor inhibitor. It is under phase 4 clinical studies in patients with severe to very severe chronic obstructive pulmonary disease (COPD).
Brand Name : Yupelri
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2024
Details:
TD-9855 (ampreloxetine) is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Lead Product(s): Ampreloxetine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TD-9855
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Lead Product(s) : Ampreloxetine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TD-9855 (ampreloxetine) is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Brand Name : TD-9855
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 09, 2023
Details:
Ampreloxetine (TD-9855) is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).
Lead Product(s): Ampreloxetine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TD-9855
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Lead Product(s) : Ampreloxetine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ampreloxetine (TD-9855) is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).
Brand Name : TD-9855
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2022
Details:
Ampreloxetine (TD-9855) is an investigational, potent, long-acting, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Lead Product(s): Ampreloxetine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TD-9855
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Lead Product(s) : Ampreloxetine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ampreloxetine (TD-9855) is an investigational, potent, long-acting, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Brand Name : TD-9855
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2022
Details:
The Company now anticipates it will approach breakeven cash flow in the second half of 2022 without the cash flows from its interest in GSK's Trelegy Ellipta (fluticasone furoate) royalties, driven by disciplined spending within R&D and the growth of YUPELRI®.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Trelegy Ellipta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Royalty Pharma
Deal Size: $1,550.0 million Upfront Cash: $1,100.0 million
Deal Type: Divestment July 13, 2022
Lead Product(s) : Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $1,550.0 million
Deal Type : Divestment
Details : The Company now anticipates it will approach breakeven cash flow in the second half of 2022 without the cash flows from its interest in GSK's Trelegy Ellipta (fluticasone furoate) royalties, driven by disciplined spending within R&D and the growth of YUP...
Brand Name : Trelegy Ellipta
Molecule Type : Small molecule
Upfront Cash : $1,100.0 million
July 13, 2022
Details:
Primary endpoint for ampreloxetine, an norepinephrine reuptake inhibitor was not statistically significant for overall population of patients which included patients with Parkinson's disease, pure autonomic failure and MSA.
Lead Product(s): Ampreloxetine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: TD-9855
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Lead Product(s) : Ampreloxetine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Primary endpoint for ampreloxetine, an norepinephrine reuptake inhibitor was not statistically significant for overall population of patients which included patients with Parkinson's disease, pure autonomic failure and MSA.
Brand Name : TD-9855
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 04, 2022
Details:
Enrollment of first patient in the Phase 4 PIFR-2 for YUPELRI® (revefenacin) is on the basis of continued investment in controlled clinical studies, that design to personalized treatment plans in order to make better-informed decisions for their COPD patients.
Lead Product(s): Revefenacin
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Yupelri
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Lead Product(s) : Revefenacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study
Details : Enrollment of first patient in the Phase 4 PIFR-2 for YUPELRI® (revefenacin) is on the basis of continued investment in controlled clinical studies, that design to personalized treatment plans in order to make better-informed decisions for their COPD pa...
Brand Name : Yupelri
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2022
Details:
Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase (JAK) inhibitor in development for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.
Lead Product(s): Nezulcitinib
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: TD-0903
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2021
Lead Product(s) : Nezulcitinib
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theravance Biopharma Report Top-Line Results From Phase 2 Study of Nezulcitinib
Details : Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase (JAK) inhibitor in development for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.
Brand Name : TD-0903
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2021
Details:
First COVID-19 patient has been dosed in a Phase 2 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19.
Lead Product(s): Nezulcitinib
Therapeutic Area: Infections and Infectious Diseases Brand Name: TD-0903
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Lead Product(s) : Nezulcitinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903
Details : First COVID-19 patient has been dosed in a Phase 2 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the potential treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19.
Brand Name : TD-0903
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2020
Details:
Theravance Biopharma received approval of TD-0903's initial Clinical Trial Application (CTA) in the United Kingdom (UK) for the Phase 1 study.
Lead Product(s): Nezulcitinib
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Lead Product(s) : Nezulcitinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Theravance Biopharma Announces First Subject Dosed In Phase 1 Study of TD-0903
Details : Theravance Biopharma received approval of TD-0903's initial Clinical Trial Application (CTA) in the United Kingdom (UK) for the Phase 1 study.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 23, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?